Eight hypertensive renal allograft recipients who had received captopril are presented. Captopril in a maximal daily dose of 250 mg enabled the withdrawal of large doses of beta-blocking agents and vasodilators. Blood pressure was satisfactorily controlled in all except one. No adverse side effects were observed other than the 'first dose' effect which resulted in transient anuria in one patient. Captopril appears to be a useful agent in the management of severe hypertension after renal transplantation.
Introduction
Hypertension is common after renal transplantation and frequently resistant to conventional antihypertensive therapy including the combination of a beta-blocker, a vasodilator and a diuretic. We report here our experience in the use of captopril, an angiotensin-converting-enzyme inhibitor active by the oral route (Vidt, Bravo and Fouad, 1982) , in eight renal allograft recipients for up to 15 months.
Patients and methods
All eight patients had hypertension which could not be adequately controlled by the standard triple therapy, i.e. the combination of a beta-blocker, a vasodilator and a diuretic. A variety of beta-blockers were often tried in the same patient. The vasodilator commonly used was hydralazine. The maximal daily dose of captopril never exceeded 250 mg, and was given in two to three divided doses. The diuretic used was frusemide. In three patients, hydralazine had to be replaced by minoxidil after maximal doses of the former proved ineffective. In these patients, the blood pressure was reasonably well controlled but hirsutism became intolerable and the patients were switched to captopril. None renal transplantation and captopril was re-introduced after a short trial of beta-blockers and hydralazine. Patient G.T. who had chronic vascular rejection and whose blood pressure initially proved resistant to captopril had transient episodes of mild thrombocytopenia (platelet count 70 x 10/litre) which reverted to normal when the dose of azathioprine was reduced. Her platelet count 15 months after commencement of captopril was 135 x 10/litre. Captopril was reduced from a maximal dose of 250 mg to 100 mg daily. Haematological indices, liver function tests and plasma urate did not show any consistent trend.
Mean 24 hr urinary protein excretion was 0-86 g when captopril was started, but fell to 0-08 g after 12 weeks of treatment. No proteinuria was detected after either 12 or 15 months of captopril.
Discussion
Early reports of leucopenia/agranulocytosis in patients treated with captopril must have caused great anxiety and concern over the use of this drug in hypertensive renal allograft recipients. Only 16 patients who were treated with captopril because of hypertension after renal transplantation have been reported (Elijovisch and Krakoff, 1980; Aurell, Delin and Herlitz, 1980; Kirchertz et al., 1981 , Hamilton et al., 1981 . One patient who received 450 mg of captopril daily had granulocytopenia (Elijovisch and Krakoff, 1980) . The fact that no leucopenic episodes were experienced although all our patients received azathioprine and captopril concurrently must be related to the small dose of captopril used. The average dose was 89 mg daily, whereas the doses used in patients who developed severe leucopenia and agranulocytosis often exceeded 200 mg daily (Vidt et al., 1982) . No proteinuria occurred de novo in our patients. Indeed as the blood pressure came under control and renal function improved, proteinuria frequently subsided. No clinical or biochemical evidence of hepatotoxicity due to captopril was detected in our study.
We conclude that captopril is extremely useful in the treatment of severe hypertension after renal transplantation. Recognizing the potential additive effects of azathioprine and captopril (Kirchertz et al., 1981) , we have not ventured beyond a maximal daily dose of 250 mg. Since the first dose effect can be very dramatic as was evident in one patient who had transient hypotension and anuria, patients are best admitted into hospital for observation at the commencement of captopril therapy. Captopril is mainly excreted in the kidney (Vidt et al., 1982) and the dose must be appropriately adjusted according to the renal function. With more experience, it may even prove the drug of choice since many hypertensive renal allograft recipients have high plasma renin activities.
